Changing paradigm in HDL metabolism and cellular effects

Future Lipidology

Volumn 4, Issue 1, 2009, Pages 17-27

  van Wijk, Diederik F ^a   Stroes, Erik S G ^a   Monajemi, Houshang ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cellular effects; CETP; HDL; Inflammation; Lipoprotein particles; Reverse cholesterol transport; SR BI

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ABC TRANSPORTER A1; APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEIN; PLACEBO; SCAVENGER RECEPTOR BI; TORCETRAPIB; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

AMINO ACID SEQUENCE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME DEFICIENCY; GENE OVEREXPRESSION; HUMAN; LIPID METABOLISM; LIPID OXIDATION; LIPOGENESIS; LYMPHOCYTE FUNCTION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; RISK REDUCTION; T LYMPHOCYTE; THROMBOCYTE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 67149121898     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17584299.4.1.17     Document Type: Review

References (103)

1. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J III: Factors of risk in the development of coronary heart disease - six year follow-up experience. The Framingham Study. Ann. Intern. Med. 55, 33-50 (1961).
2. Brewer HB Jr: Increasing HDL cholesterol levels. N. Engl. J. Med. 350(15), 1491-1494 (2004).
3. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N: HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell. Metab. 7(5), 365-375 (2008).
4. Hegele RA, Little JA, Vezina C et al.: Hepatic lipase deficiency: clinical, biochemical, and molecular genetic characteristics. Arterioscler. Thromb. 13(5), 720-728 (1993).
5. Berard AM, Foger B, Remaley A et al.: High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase Nat. Med. 3(7), 744-749 (1997).
6. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M: Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271(5248), 518-520 (1996).
7. Trigatti BL, Krieger M, Rigotti A: Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23(10), 1732-1738 (2003).
8. Yan D, Navab M, Bruce C, Fogelman AM, Jiang XC: PLTP deficiency improves the anti-Inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity J. Lipid Res. 45(10), 1852-1858 (2004).
9. Hirano K, Yamashita S, Sakai N et al.: Molecular defect and atherogenicity in cholesteryl ester transfer protein deficiency. Ann. NY Acad. Sci. 748, 599-602 (1995).
10. Boekholdt SM, Kuivenhoven JA, Wareham NJ et al.: Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition) - Norfolk population study. Circulation 110(11), 1418-1423 (2004).
11. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Buga GM, Fogelman AM: Peptide mimetics of apolipoproteins improve HDL function. J. Clin. Lipidol. 1(2), 142-147 (2007).
12. Shaw JA, Bobik A, Murphy A et al.: Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ. Res. 103(10), 1084-1091 (2008).
13. Navab M, Imes SS, Hama SY et al.: Monocyte transmigration induced by modification of low-density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. 88(6), 2039-2046 (1991).
14. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM: A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J. Lipid Res. 42 (8), 1308-1317 (2001).
15. Navab M, Yu R, Gharavi N et al.: High-density lipoprotein: antioxidant and anti-inflammatory properties. Curr. Atheroscler. Rep. 9(3), 244-248 (2007).
16. Imaizumi K, Havel RJ, Fainaru M, Vigne JL: Origin and transport of the A-I and arginine-rich apolipoproteins in mesenteric lymph of rats. J. Lipid Res. 19(8), 1038-1046 (1978).
17. Brewer HB Jr, Fairwell T, LaRue A, Ronan R, Houser A, Bronzert TJ: The amino acid sequence of human APOA-I, an apolipoprotein isolated from high density lipoproteins. Biochem. Biophys. Res. Commun. 80(3), 623-630 (1978).
18. Wang N, Silver DL, Thiele C, Tall AR: ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J. Biol. Chem. 276(26), 23742-23747 (2001).
19. Timmins JM, Lee JY, Boudyguina E et al.: Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J. Clin. Invest. 115(5), 1333-1342 (2005).
20. Brunham LR, Kruit JK, Iqbal J et al.: Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Invest. 116(4), 1052-1062 (2006).
21. Denis M, Landry YD, Zha X: ATP-binding cassette A1-mediated lipidation of apolipoprotein A-I occurs at the plasma membrane and not in the endocytic compartments. J. Biol. Chem. 283 (23), 16178-16186 (2008).
22. Jonas A: Lecithin cholesterol acyltransferase. Biochim. Biophys. Acta 1529 (1-3), 245-256 (2000).
23. Hovingh GK, de Groot E, van der Steeg W et al.: Inherited disorders of HDL metabolism and atherosclerosis. Curr. Opin. Lipidol. 16(2), 139-145 (2005).
24. Carlson LA, Philipson B: Fish-eye disease. A new familial condition with massive corneal opacities and dyslipoproteinaemia. Lancet 2(8149), 922-924 (1979).
25. Brousseau ME, Santamarina-Fojo S, Vaisman BL et al.: Overexpression of human lecithin:cholesterol acyltransferase in cholesterol-fed rabbits: LDL metabolism and HDL metabolism are affected in a gene dose-dependent manner. J. Lipid Res. 38(12), 2537-2547 (1997).
26. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406(6792), 203-207 (2000).
27. Morehouse LA, Sugarman ED, Bourassa PA et al.: Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J. Lipid Res. 48(6), 1263-1272 (2007).
28. Barter PJ, Caulfield M, Eriksson M et al.: Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357(21), 2109-2122 (2007).
29. Kastelein JJ, van Leuven SI, Burgess L et al.: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356(16), 1620-1630 (2007).
30. Joy T, Hegele RA: Is raising HDL a futile strategy for atheroprotection? Nat. Rev. Drug Discov. 7(2), 143-155 (2008).
31. El Harchaoui K, van der Steeg WA, Stroes ES, Kastelein JJ: The role of CETP inhibition in dyslipidemia. Curr. Atheroscler. Rep. 9(2), 125-133 (2007).
32. Krishna R, Anderson MS, Bergman AJ et al.: Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled Phase I studies. Lancet 370(9603), 1907-1914 (2007).
33. Day JR, Albers JJ, Lofton-Day CE et al.: Complete cDNA encoding human phospholipid transfer protein from human endothelial cells. J. Biol. Chem. 269(12), 9388-9391 (1994).
34. Tu AY, Nishida HI, Nishida T: High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. J. Biol. Chem. 268(31), 23098-23105 (1993).
35. Pussinen PJ, Jauhiainen M, Metso J et al.: Binding of phospholipid transfer protein (PLTP) to apolipoproteins A-I and A-II: location of a PLTP binding domain in the amino terminal region of apoA-I. J. Lipid Res. 39(1), 152-161 (1998).
36. Jiang XC, Bruce C, Mar J et al.: Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J. Clin. Invest. 103(6), 907-914 (1999).
37. Moerland M, Samyn H, van Gent T et al.: Acute elevation of plasma PLTP activity strongly increases pre-existing atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28(7), 1277-1282 (2008).
38. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M: Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271(5248), 518-520 (1996).
39. Liadaki KN, Liu T, Xu S et al.: Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. Effect of lipid association and APOA-I mutations on receptor binding. J. Biol. Chem. 275 (28), 21262-21271 (2000).
40. Wang N, Arai T, Ji Y, Rinninger F, Tall AR: Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice. J. Biol. Chem. 273(49), 32920-32926 (1998).
41. Arai T, Wang N, Bezouevski M, Welch C, Tall AR: Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J. Biol. Chem. 274(4), 2366-2371 (1999).
42. Huszar D, Varban ML, Rinninger F et al.: Increased LDL cholesterol and atherosclerosis in LDL receptor-deficient mice with attenuated expression of scavenger receptor B1. Arterioscler. Thromb. Vasc. Biol. 20(4), 1068-1073 (2000).
43. Ruel IL, Couture P, Gagne C et al.: Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians. J. Lipid Res. 44(8), 1508-1514 (2003).
44. Lambert G, Amar MJ, Martin P et al.: Hepatic lipase deficiency decreases the selective uptake of HDL-cholesteryl esters in vivo. J. Lipid Res. 41(5), 667-672 (2000).
45. Rouhani N, Young E, Chatterjee C, Sparks DL: HDL composition regulates displacement of cell surface-bound hepatic lipase. Lipids 43 (9), 793-804 (2008).
46. Ji ZS, Dichek HL, Miranda RD, Mahley RW: Heparan sulfate proteoglycans participate in hepatic lipase and apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins. J. Biol. Chem. 272(50), 31285-31292 (1997).
47. Ishida T, Choi S, Kundu RK et al.: Endothelial lipase is a major determinant of HDL level. J. Clin. Invest. 111(3), 347-355 (2003).
48. Jaye M, Lynch KJ, Krawiec J et al.: A novel endothelial-derived lipase that modulates HDL metabolism. Nat. Genet. 21(4), 424-428 (1999).
49. Maugeais C, Tietge UJ, Broedl UC et al.: Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase. Circulation 108(17), 2121-2126 (2003).
50. Badellino KO, Wolfe ML, Reilly MP, Rader DJ: Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med. 3(2), E22 (2006).
51. Badellino KO, Wolfe ML, Reilly MP, Rader DJ: Endothelial lipase is increased in vivo by inflammation in humans. Circulation 117(5), 678-685 (2008).
52. Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC: High-density lipoprotein function: recent advances. J. Am. Coll. Cardiol. 46(10), 1792-1798 (2005).
53. Movva R, Rader DJ: Laboratory assessment of HDL heterogeneity and function. Clin. Chem. 54(5), 788-800 (2008).
54. Levels JH, Bleijlevens B, Rezaee F, Aerts JM, Meijers JC: SELDI-TOF mass spectrometry of high-density lipoprotein. Proteome Sci. 5, 15 (2007).
55. Vaisar T, Pennathur S, Green PS et al.: Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 117(3), 746-756 (2007).
56. deGoma EM, deGoma RL, Rader DJ: Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol. 51(23), 2199-2211 (2008).
57. Reape TJ, Groot PH: Chemokines and atherosclerosis. Atherosclerosis 147(2), 213-225 (1999).
58. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M: Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem. Biophys. Res. Commun. 318(3), 680-683 (2004).
59. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ: High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 15(11), 1987-1994 (1995).
60. Park SH, Park JH, Kang JS, Kang YH: Involvement of transcription factors in plasma HDL protection against TNF-α-induced vascular cell adhesion molecule-1 expression. Int. J. Biochem. Cell. Biol. 35(2), 168-182 (2003).
61. Davies MJ, Gordon JL, Gearing AJ et al.: The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J. Pathol. 171(3), 223-229 (1993).
62. Lawrence MB, Springer TA: Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell 65(5), 859-873 (1991).
63. Springer TA: Adhesion receptors of the immune system. Nature 346(6283), 425-434 (1990).
64. Walpola PL, Gotlieb AI, Cybulsky MI, Langille BL: Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress. Thromb. Vasc. Biol. 15(1), 2-10 (1995).
65. Krejcy K, Schwarzacher S, Ferber W, Plesch C, Cybulsky MI, Weidinger FF: Expression of VCAM-1 in rabbit iliac arteries is associated with vasodilator dysfunction of regenerated endothelium following balloon injury. Atherosclerosis 122(1), 59-67 (1996).
66. Li H, Cybulsky MI, Gimbrone MA Jr, Libby P: An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler. Thromb. 13(2), 197-204 (1993).
67. Carlos TM, Schwartz BR, Kovach NL et al.: Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood 76 (5), 965-970 (1990).
68. Calabresi L, Franceschini G, Sirtori CR et al.: Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoptoteins. Biochem. Biophys. Res. Commun. 238(1), 61-65 (1997).
69. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ: High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 15(11), 1987-1994 (1995).
70. Nofer JR, Geigenmuller S, Gopfert C, Assmann G, Buddecke E, Schmidt A: High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells. Biochem. Biophys. Res. Commun. 310(1), 98-103 (2003).
71. Cockerill GW, Huehns TY, Weerasinghe A et al.: Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 103(1), 108-112 (2001).
72. Nicholls SJ, Lundman P, Harmer JA et al.: Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. J. Am. Coll. Cardiol. 48(4), 715-720 (2006).
73. Nofer JR, van der Giet M, Tolle M et al.: HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 113(4), 569-581 (2004).
74. Kimura T, Tomura H, Mogi C et al.: Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J. Biol. Chem. 281(49), 37457-37467 (2006).
75. Yuhanna IS, Zhu Y, Cox BE et al.: High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7(7), 853-857 (2001).
76. Ramet ME, Ramet M, Lu Q et al.: High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life. J. Am. Coll. Cardiol. 41(12), 2288-2297 (2003).
77. Berliner JA, Subbanagounder G, Leitinger N, Watson AD, Vora D: Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc. Med. 11(3-4), 142-147 (2001).
78. Gargalovic PS, Imura M, Zhang B et al.: Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. Proc. Natl. Acad. Sci. USA 103(34), 12741-12746 (2006).
79. Gharavi NM, Gargalovic PS, Chang I et al.: High-density lipoprotein modulates oxidized phospholipid signaling in human endothelial cells from proinflammatory to anti-inflammatory. Arterioscler. Thromb. Vasc. Biol. 27(6), 1346-1353 (2007).
80. Norata GD, Callegari E, Inoue H, Catapano AL: HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/ PGI-synthase coupling. Arterioscler. Thromb. Vasc. Biol. 24(5), 871-877 (2004).
81. Ashby DT, Rye KA, Clay MA, Vadas MA, Gamble JR, Barter PJ: Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 18(9), 1450-1455 (1998).
82. Calabresi L, Gomaraschi M, Franceschini G: Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler. Thromb. Vasc. Biol. 23(10), 1724-1731 (2003).
83. Mineo C, Yuhanna IS, Quon MJ, Shaul PW: High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J. Biol. Chem. 278(11), 9142-9149 (2003).
84. Norata GD, Bjork H, Hamsten A, Catapano AL, Eriksson P: High-density lipoprotein subfraction 3 decreases ADAMTS-1 expression induced by lipopolysaccharide and tumor necrosis factor-α in human endothelial cells. Matrix Biol. 22(7), 557-560 (2004).
85. Tedgui A, Mallat Z: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 86(2), 515-581 (2006).
86. Murphy AJ, Woollard KJ, Hoang A et al.: High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler. Thromb. Vasc. Biol. 28(11), 2071-2077 (2008).
87. Ardans JA, Economou AP, Martinson JM Jr, Zhou M, Wahl LM: Oxidized low-density and high-density lipoproteins regulate the production of matrix metalloproteinase-1 and -9 by activated monocytes. J. Leukoc. Biol. 71(6), 1012-1018 (2002).
88. Terasaka N, Wang N, Yvan-Charvet L, Tall AR: High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1. Proc. Natl. Acad. Sci. USA 104(38), 15093-15098 (2007).
89. Thompson PA, Kitchens RL: Native high-density lipoprotein augments monocyte responses to lipopolysaccharide (LPS) by suppressing the inhibitory activity of LPS-binding protein. J. Immunol. 177(7), 4880-4887 (2006).
90. Hyka N, Dayer JM, Modoux C et al.: Apolipoprotein A-I inhibits the production of interleukin-1β and tumor necrosis factor-α by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97(8), 2381-2389 (2001).
91. Scanu A, Molnarfi N, Brandt KJ, Gruaz L, Dayer JM, Burger D: Stimulated T cells generate microparticles, which mimic cellular contact activation of human monocytes: differential regulation of pro- and anti-inflammatory cytokine production by high-density lipoproteins. J. Leukoc. Biol. 83(4), 921-927 (2008).
92. Cettour-Rose P, Nguyen TX, Serrander L et al.: T cell contact-mediated activation of respiratory burst in human polymorpho-nuclear leukocytes is inhibited by high-density lipoproteins and involves CD18. J. Leukoc. Biol. 77(1), 52-58 (2005).
93. Curtiss LK, Plow EF: Interaction of plasma lipoproteins with human platelets. Blood 64(2), 365-374 (1984).
94. Koller E, Koller F, Doleschel W: Specific binding sites on human blood platelets for plasma lipoproteins. Hoppe Seylers Z Physiol. Chem. 363(4), 395-405 (1982).
95. Ozsavci D, Yardimci T, Demirel GY, Uras F, Hekim N, Ulutin ON: Apo A-I binding to platelets detected by flow cytometry. Thromb. Res. 103(2), 117-122 (2001).
96. Aviram M, Brook JG: Platelet interaction with high and low density lipoproteins. Atherosclerosis 46(3), 259-268 (1983).
97. Aviram M, Brook JG: Characterization of the effect of plasma lipoproteins on platelet function in vitro. Haemostasis 13(6), 344-350 (1983).
98. Hassall DG, Owen JS, Bruckdorfer KR: The aggregation of isolated human platelets in the presence of lipoproteins and prostacyclin. Biochem. J. 216(1), 43-49 (1983).
99. Nofer JR, Walter M, Kehrel B et al.: HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-trisphosphate. Arterioscler. Thromb. Vasc. Biol. 18(6), 861-869 (1998).
100. Barlage S, Boettcher D, Boettcher A, Dada A, Schmitz G: High density lipoprotein modulates platelet function. Cytometry A 69(3), 196-199 (2006).
101. Assinger A, Schmid W, Eder S, Schmid D, Koller E, Volf I: Oxidation by hypochlorite converts protective HDL into a potent platelet agonist. FEBS Lett. 582(5), 778-784 (2008).
102. Naqvi TZ, Shah PK, Ivey PA et al.: Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am. J. Cardiol. 84(9), 1011-1017 (1999).
103. deGoma EM, deGoma RL, Rader DJ: Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol. 51(23), 2199-2211 (2008).